Navigation Links
Genes and biomarkers that allow doctors to choose the right therapy for the right patient

that represent the subtypes observed in analyses of primary tumors.

By correlating the responses of these cells to targeted therapeutic drugs, the researchers were able to identify the molecular characteristics of cells that were most sensitive to the drugs. They tested their approach by analyzing responses of the cell line panel to lapatinib, a duel inhibitor of EGFR and ErbB2 and CI-1040, a MEK enzyme inhibitor. These studies defined molecular signatures that predicted individual responses among the cell lines to the drugs. For Lapatinib, the strongest correlate of response was amplification and over expression of ErBB2, consistent with clinical experience. For CI-1040, changes in the MEK pathway were most strongly associated with response. Predictors based on combinations of molecular correlates of response were able to quantitatively predict individual cell line responses.

"The concordance of our markers of response to lapatinib with those observed clinically suggests that the molecular markers identified in the cell line collection can be used to guide the use and testing of other approved and experimental drugs," Gray said. "This is important since it is logistically and financially impossible to test all of the experimental medicines in each cancer subtype. This ‘systems?approach suggests a way to prioritize drugs for use in patients and for initial clinical tests."

According to Gray, a large of number of emerging therapeutic agents should be prioritized for testing in the subtypes of breast cancer along with other cancers and their subtypes. When therapies are ineffective, they may produce harmful side effects and decrease a patient’s quality of life.

KRAS mutation in colorectal cancer is a predictive factor of response and progression free survival in patients treated with Cetuximab: Abstract 5671

Mutations in the KRAS oncogene could predict a lack of response to the drug cetuximab in patie
'"/>

Source:American Association for Cancer Research


Page: 1 2 3 4 5 6

Related biology news :

1. Genes In The Interferon System Important In Systemic Lupus Erythematosus
2. Protein Packages Found To Activate Genes; May Be What Regulates Development And Disease
3. VCU Researchers Identify Networks Of Genes Responding To Alcohol In The Brain
4. Genpathway and Baylor College of Medicine Identify New Genes in Breast Cancer
5. Where Bacteria Get Their Genes
6. Genes linked to treatment resistance in children with leukemia
7. Noise And Delays Explain Why Some Genes Oscillate In Activity
8. Genes involved in biofilms
9. Genes involved in cell growth and cell division identified
10. Genes affecting blood pressure change as children become adults
11. Genes discovered that allow gum disease bacterium to invade arteries
Post Your Comments:
(Date:12/17/2014)... 16, 2014 Valencell, a leader in performance biometric ... to industry leaders such as Intel, Jabra, Atlas, and ... wearable products. These products will be showcased at CES ... Vegas . "Our partners choose ...
(Date:12/15/2014)... DUBLIN , Dec. 12, 2014 Research and Markets ... of the "Global Facial Recognition Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 Facial recognition is a technology ... measures the overall facial feature of a person such ...
(Date:12/11/2014)...  That blood pressure plays a role in human health has ... term for high blood pressure – was first described as ... that,s used in measuring blood pressure was invented in 1896. ... hypertension, its triggers and its effects. In fact, recent findings ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... Nov. 12, 2013 One of the most comprehensive ... today, demonstrating an unprecedented level of genetic variation that ... ovarian cancer. The study highlights potential new pathways for ... multiple disease sites may be required for effective targeted ...
... as clear as glass, or why bakers use sugar, even ... in the American Chemical Society,s (ACS,) latest Bytesize Science ... . "Everything that happens in the kitchen is science," ... of it, you,re going to have more power over your ...
... protein, they tend to eat a small amount at ... at dinner. New research presented today at The ... eating high protein sausage and egg-based breakfasts curbed hunger ... and syrup) or skipping breakfast, in 18-55-year-old women., ...
Cached Biology News:Clinical ovarian cancers display extensive genetic heterogeneity, study suggests multiple treatment 2Clinical ovarian cancers display extensive genetic heterogeneity, study suggests multiple treatment 3
(Date:12/24/2014)... Dec. 24, 2014  United Therapeutics Corporation (NASDAQ: ... MDT ) has submitted a pre-market approval application ... the use of Medtronic,s SynchroMed ® II implantable ... use with United Therapeutics, Remodulin ® (treprostinil) Injection ...
(Date:12/24/2014)... 24, 2014   BioLife Solutions , Inc. (NASDAQ: ... clinical grade hypothermic storage and cryopreservation freeze ... cells and tissues  ("BioLife" or the "Company"), today announced that ... May 4, 2015 (the "Annual Meeting"). Because the ...
(Date:12/24/2014)... Earlier this year in a June 24 international ... Stem Cell Technology Center, LLC ( ASCTC ) focused attention ... adult tissue stem cells. His title “Asymmetric Self-Renewal by ... Future,” embodied the essence of his message to congress participants. ...
(Date:12/24/2014)... 23, 2014 According to Ross Selinger, President ... of ITRA Global, the national office market continues to be ... This is evidenced by the third quarter’s surprising 3.9% GDP, ... Low energy costs have held inflation down and the Fed ...
Breaking Biology Technology:United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3
... MSEDMONTON, March 17 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: ... sclerosis (MS), today announced financial and operational results for ... demonstrated the ability to safely affect MS progression in ... of the Canadian/European trial (MAESTRO-01) in the second half ...
... LONDON and WASHINGTON, March 17 Gentag, Inc. (Gentag) ... VCG & Associates Inc. and Talisman Management Ltd. to ... of all or parts of its IP portfolio. ... pharmaceutical and medical diagnostic uses on a global or ...
... AMGN ) will present at the Cowen and ... at the Boston Marriott Copley Place, Boston, Mass., beginning at ... President of North American Commercial Operations, will present. Live audio ... can be accessed from Amgen,s Web site, www.amgen.com , ...
Cached Biology Technology:BioMS Medical Announces 2008 Year End Results 2BioMS Medical Announces 2008 Year End Results 3BioMS Medical Announces 2008 Year End Results 4BioMS Medical Announces 2008 Year End Results 5BioMS Medical Announces 2008 Year End Results 6BioMS Medical Announces 2008 Year End Results 7BioMS Medical Announces 2008 Year End Results 8BioMS Medical Announces 2008 Year End Results 9BioMS Medical Announces 2008 Year End Results 10BioMS Medical Announces 2008 Year End Results 11Gentag, Inc. Engages US and UK Firms to Explore Strategic Options 2
... Product Mouse monoclonal [SPM278] to ... Small cell lung carcinoma N592 live cells ... with Human. Not yet tested in other ... of the major glycoproteins of basement membrane, ...
TLN2 Antibody...
Chicken polyclonal to Thaumatin 2 ( Abpromise for all tested applications). Antigen: Full length Thaumatin 2...
XIAP Antibody...
Biology Products: